Data-Driven Discovery of Immune Contexture Biomarkers

Background: Features characterizing the immune contexture (IC) in the tumor microenvironment can be prognostic and predictive biomarkers. Identifying novel biomarkers can be challenging due to complex interactions between immune and tumor cells and the abundance of possible features. Methods: We describe an approach for the data-driven identification of IC biomarkers. For this purpose, we provide mathematical definitions of different feature classes, based on cell densities, cell-to-cell distances, and spatial heterogeneity thereof. Candidate biomarkers are ranked according to their potential for the predictive stratification of patients. Results: We evaluated the approach on a dataset of colorectal cancer patients with variable amounts of microsatellite instability. The most promising features that can be explored as biomarkers were based on cell-to-cell distances and spatial heterogeneity. Both the tumor and non-tumor compartments yielded features that were potentially predictive for therapy response and point in direction of further exploration. Conclusion: The data-driven approach simplifies the identification of promising IC biomarker candidates. Researchers can take guidance from the described approach to accelerate their biomarker research.

[1]  Jakob Nikolas Kather,et al.  Topography of cancer-associated immune cells in human solid tumors , 2018, eLife.

[2]  F. Marincola,et al.  International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study , 2018, The Lancet.

[3]  Nathalie Harder,et al.  Tissue Phenomics for prognostic biomarker discovery in low- and intermediate-risk prostate cancer , 2018, Scientific Reports.

[4]  J. Taube,et al.  Implications of the tumor immune microenvironment for staging and therapeutics , 2018, Modern Pathology.

[5]  Laurence Zitvogel,et al.  The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.

[6]  F. Aeffner,et al.  Abstract 1710: Providing confidence around computational tissue analysis using heterogeneity assessments , 2017 .

[7]  Karl Garsha,et al.  Fully automated 5-plex fluorescent immunohistochemistry with tyramide signal amplification and same species antibodies. , 2017, Laboratory investigation; a journal of technical methods and pathology.

[8]  Christopher. Simons,et al.  Machine learning with Python , 2017 .

[9]  P. Hoff,et al.  The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment , 2017, Current Treatment Options in Oncology.

[10]  I. Mellman,et al.  Elements of cancer immunity and the cancer–immune set point , 2017, Nature.

[11]  M. Dwyer,et al.  Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. , 2016, Journal of the National Comprehensive Cancer Network : JNCCN.

[12]  James Ziai,et al.  Mismatch repair deficiency testing in clinical practice , 2016, Expert review of molecular diagnostics.

[13]  G. Grabenbauer,et al.  Cell-to-cell distances between tumor-infiltrating inflammatory cells have the potential to distinguish functionally active from suppressed inflammatory cells , 2016, Oncoimmunology.

[14]  Ronald N. Germain,et al.  Immune homeostasis enforced by co-localized effector and regulatory T cells , 2015, Nature.

[15]  Arvydas Laurinavicius,et al.  A methodology for comprehensive breast cancer Ki67 labeling index with intra-tumor heterogeneity appraisal based on hexagonal tiling of digital image analysis data , 2015, Virchows Archiv.

[16]  Carsten Denkert,et al.  Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial. , 2015, JAMA oncology.

[17]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[18]  T. Aparicio,et al.  PD-1 blockade in tumors with mismatch-repair deficiency , 2015 .

[19]  M. Zanetti.  Tapping CD4 T Cells for Cancer Immunotherapy: The Choice of Personalized Genomics , 2015, The Journal of Immunology.

[20]  Sidra Nawaz,et al.  Mapping spatial heterogeneity in the tumor microenvironment: a new era for digital pathology , 2015, Laboratory Investigation.

[21]  G. Parker,et al.  Imaging Intratumor Heterogeneity: Role in Therapy Response, Resistance, and Clinical Outcome , 2014, Clinical Cancer Research.

[22]  Molin Wang,et al.  Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  F. Marincola,et al.  Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours , 2013, The Journal of pathology.

[24]  G. Grabenbauer,et al.  Critical role of spatial interaction between CD8+ and Foxp3+ cells in human gastric cancer: the distance matters , 2014, Cancer Immunology, Immunotherapy.

[25]  R. Bischoff,et al.  Comprehensive biomarker discovery and validation for clinical application , 2013 .

[26]  Pierre Gançarski,et al.  Combat or surveillance? Evaluation of the heterogeneous inflammatory breast cancer microenvironment , 2013, The Journal of pathology.

[27]  Andrew H. Beck,et al.  Systematic Analysis of Breast Cancer Morphology Uncovers Stromal Features Associated with Survival , 2011, Science Translational Medicine.

[28]  Ian O Ellis,et al.  Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Gaël Varoquaux,et al.  Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..

[30]  Janice Branson,et al.  Epigenetic Modification of the FMR1 Gene in Fragile X Syndrome Is Associated with Differential Response to the mGluR5 Antagonist AFQ056 , 2011, Science Translational Medicine.

[31]  J. Shia.  Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. , 2008, The Journal of molecular diagnostics : JMD.

[32]  Isabelle Guyon,et al.  An Introduction to Variable and Feature Selection , 2003, J. Mach. Learn. Res..

[33]  Judith S. Olson,et al.  Distance Matters , 2000, Hum. Comput. Interact..

[34]  Andrew P. Bradley,et al.  The use of the area under the ROC curve in the evaluation of machine learning algorithms , 1997, Pattern Recognit..

[35]  Pat Langley,et al.  Induction of One-Level Decision Trees , 1992, ML.

[36]  K. Shadan,et al.  Available online: , 2012 .